The 26 most recent market catalysts affecting $EW, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 16, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Adjusts Price Target on Edwards Lifesciences
Wells Fargo analyst Larry Biegelsen updated his outlook on Edwards Lifesciences, raising the price target from $113 to $121 and reiterating a 'buy' rating. This adjustment signals …
Nov 13, 2026
Corporate Catalyst
Bearish
Impact 55
Edwards Lifesciences Resolves HSR Act Allegations via Consent Judgment
Edwards Lifesciences has resolved allegations from the U.S. government regarding a violation of the Hart-Scott-Rodino Act during its acquisition of JC Medical and investment in Gen…
Nov 11, 2026
Corporate Catalyst
Bullish
Impact 65
TD Cowen Updates Analyst Coverage on Edwards Lifesciences
TD Cowen has updated its analyst coverage for Edwards Lifesciences, raising the price target from $117 to $121 but simultaneously issuing a 'sell' rating. This action is significan…
Nov 6, 2026
Corporate Catalyst
Neutral
Impact 75
Multiple Financial Institutions Adjust Price Targets for Edwards Lifesciences
On November 5, 2026, several prominent financial institutions adjusted their outlook on Edwards Lifesciences. This wave of positive revisions, including an upgrade from Truist Secu…
Nov 5, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Upgrades Edwards Lifesciences Price Target
BTIG has upgraded its price target for Edwards Lifesciences (EW) from $110 to $115, signaling increased confidence in the company's future performance. This move, coupled with a ma…
Nov 5, 2026
Corporate Catalyst
Bullish
Impact 75
Edwards Lifesciences Receives FDA Approvals for PASCAL and EVOQUE Systems
Edwards Lifesciences announced significant regulatory approvals for its PASCAL and EVOQUE systems, expanding its offerings for minimally invasive treatment of mitral and tricuspid …
Nov 4, 2026
Corporate Catalyst
Neutral
Impact 92
Edwards Lifesciences Reports Third Quarter 2026 Financial Results
Edwards Lifesciences announced robust Q3 2026 earnings, with sales increasing by 10.5% and adjusted EPS up 19%. This strong performance was driven by significant growth in both its…
Nov 2, 2026
Corporate Catalyst
Bullish
Impact 75
Edwards Lifesciences Announces Positive Results from CLASP II TR Trial for PASCAL System
Edwards Lifesciences reported that its PASCAL system for tricuspid repair met its six-month primary endpoint in the CLASP II TR trial, demonstrating superiority compared to medical…
Nov 2, 2026
Corporate Catalyst
Bullish
Impact 75
PROGRESS Trial Shows Edwards TAVR Superior to Clinical Surveillance for Moderate Aortic Stenosis
Edwards Lifesciences reported highly positive results from its PROGRESS trial, demonstrating that its TAVR technology is superior to clinical surveillance for patients with moderat…
Oct 29, 2026
Corporate Catalyst
Bullish
Impact 55
Edwards Lifesciences Partners with egnite and Pathway Labs for Structural Heart Disease Identification
Edwards Lifesciences is investing in a pilot program to advance the early identification of structural heart disease, partnering with egnite and Pathway Labs. This initiative is si…
Oct 29, 2026
Corporate Catalyst
Neutral
Impact 65
First Tricuspid Valve Repair Performed Using Edwards Lifesciences' PASCAL Precision System
Edwards Lifesciences' PASCAL Precision system has achieved a significant milestone with the first U.S. tricuspid valve repair. This event, following recent FDA approval, indicates …
Oct 21, 2026
Corporate Catalyst
Bullish
Impact 75
Edwards Lifesciences Receives FDA Approval for Tricuspid Valve Repair System
Edwards Lifesciences announced FDA approval for its tricuspid valve repair system, a significant regulatory milestone. This approval allows EW to offer a new treatment option for p…
Oct 16, 2026
Corporate Catalyst
Bearish
Impact 75
FDA Flags High-Risk Heart Device Recall At Edwards Lifesciences After Patient Death
Edwards Lifesciences is recalling specific lots of its Commander M delivery systems after reports of balloons bursting during procedures, resulting in one patient death and a serio…
Oct 16, 2026
Corporate Catalyst
Bearish
Impact 75
Reported Earlier, Edwards Lifesciences Tells Customers To Remove Four Lots Of Commander M Delivery Systems For SAPIEN M3; FDA Flags Potentially High-Risk Issue
The filing, though sparse, points to an FDA 'Early Alert' concerning Edwards Lifesciences' Commander M Delivery Systems for SAPIEN M3. The headline explicitly states that Edwards L…
Oct 7, 2026
Corporate Catalyst
Neutral
Impact 65
Barclays Initiates Coverage On Edwards Lifesciences with Overweight Rating, Announces Price Target of $110
Barclays analyst Christopher Pasquale initiated coverage on Edwards Lifesciences with an 'Overweight' rating and set a price target of $110. This event is significant for EW as new…
Oct 2, 2026
Corporate Catalyst
Bullish
Impact 78
Edwards Lifesciences Secures FDA Approval for First Expandable Pediatric Heart Valve
Edwards Lifesciences secured FDA approval for its AUTUS Size-Adjustable Valve, a groundbreaking device designed for pediatric pulmonary valve replacement. This is a significant pos…
Oct 1, 2026
Corporate Catalyst
Bullish
Impact 75
Edwards Lifesciences Says FDA Approves AUTUS Size-Adjustable Valve, Surgical Pulmonary Valve Designed For Pediatric Patients With Congenital Heart Disease
Edwards Lifesciences received FDA approval for its AUTUS Size-Adjustable Valve, a surgical pulmonary valve specifically designed for pediatric patients with congenital heart diseas…
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 55
JP Morgan Maintains Overweight on Edwards Lifesciences, Raises Price Target to $105
JP Morgan's analyst Robbie Marcus maintained an 'Overweight' rating on Edwards Lifesciences and raised the price target from $100 to $105. This action signals continued confidence …
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 85
Edwards Earnings Add Fuel To Bullish MedTech Thesis, Analyst Says
Edwards Lifesciences exceeded Wall Street's Q2 earnings and revenue estimates, reporting adjusted earnings of 78 cents per share against an estimated 74 cents, and revenue of $1.74…
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 85
Edwards Lifesciences shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance.
Edwards Lifesciences' strong earnings and optimistic long-term guidance are a significant positive catalyst for the company, indicating strong operational execution and market dema…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 92
Edwards Lifesciences shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance.
Edwards Lifesciences' impressive Q2 earnings beat and raised long-term guidance are a major positive catalyst, directly impacting EW shares. This strong performance suggests robust…
Jul 23, 2026
Corporate Catalyst
Neutral
Impact 75
Edwards Lifesciences Sees Q3 Adj EPS $0.71-$0.77 vs $0.74 Est; Sees Sales $1.630B-$1.710B vs $1.689B Est
Edwards Lifesciences (EW) released its Q3 guidance, projecting adjusted EPS of $0.71-$0.77, which is largely in line with the analyst estimate of $0.74. However, the company's sale…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 92
Edwards Lifesciences Q2 Adj. EPS $0.78 Beats $0.74 Estimate, Sales $1.741B Beat $1.700B Estimate
Edwards Lifesciences announced Q2 adjusted EPS of $0.78, beating the consensus estimate of $0.74 by 5.41%, and sales of $1.741 billion, surpassing the $1.700 billion estimate by 2.…
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 55
Mizuho Maintains Outperform on Edwards Lifesciences, Raises Price Target to $105
Mizuho analyst Anthony Petrone maintained an 'Outperform' rating on Edwards Lifesciences (EW) and raised the price target from $100 to $105. This action signals an analyst's increa…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on Edwards Lifesciences, Raises Price Target to $110
RBC Capital analyst Shagun Singh maintained an Outperform rating on Edwards Lifesciences and raised the price target from $100 to $110. This action signals increased confidence fro…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.